TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7396472
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of probenecid administered concomitantly with 2 g of cefoxitin intravenously
Study: 7396472
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of probenecid administered 1 hour prior to 2 g of cefoxitin intravenously
Study: 7396472
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of probenecid administered with 2 g of cefoxitin intramuscularly
Study: 7396472
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of probenecid administered before 2 g of cefoxitin intravenously
Study: 23314231
Drug: Subthreshold argon
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold argon laser therapy
Study: 19563191
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at acupoint combined with warming needle therapy
Study: 17984151
Drug: Coaching intervention
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching intervention (10 weekly sessions, 15-30 minutes each over three months)
Study: 8260371
Drug: Recombinant interleukin
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interleukin 2 (rIL-2) 120 h continuous infusion at 18 x 10(6) iu m‐2 day followed by three injections of 5FU 600 mg m‐2 at weekly intervals
Study: 8260371
Drug: Weekly 5FU
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 5FU (after initial treatment with rIL-2)
Study: 3978007
Drug: Fentanyl continuous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl continuous i.v. infusion at 1.5 microgram kg‐1 min‐1
Study: 3978007
Drug: Fentanyl continuous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl continuous i.v. infusion at 0.5 microgram kg‐1 min‐1
Study: 25730290
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX‐A) - single dose of 10 units per kilogram body weight
Study: 22591059
Drug: Step-up treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up treatment strategy (antacid 4dd + placebo 1dd)
Study: 22591059
Drug: Step-down treatment
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down treatment strategy (proton pump inhibitor 1dd + placebo 4dd)
Study: 22591059
Drug: Step 3
Normalized name: Nicotine Patch Step 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 3 (five pills/day, placebo and verum vice versa from step 1)
Study: 22591059
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication vs. placebo
Study: 18950330
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (2 mcg x kg(‐1)) and infraorbital nerve block with 0.5 ml preservative-free normal saline on each side
Study: 18950330
Drug: Bilateral infraorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral infraorbital nerve blocks with 0.5 ml on each side of 0.25% bupivacaine and 2 ml of preservative-free saline solution intravenously
Study: 16192766
Drug: Rapid crystalloid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid crystalloid infusion (group 1)
Study: 16192766
Drug: Minimal maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal maintenance rate crystalloid infusion (group 0)
Study: 10385641
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment for 4 weeks
Study: 1802393
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg NGT
Study: 6828256
Drug: Aqueous suspension
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suspension of cofosfolactamines
Study: 6828256
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of cofosfolactamines
Study: 29850450
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil group (receiving 20% of total daily energy from olive oil)
Study: 27267431
Drug: Lispro administered
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lispro administered by QS-M needle-free jet injector
Study: 24598007
Drug: Ciclesonide nasal
Normalized name: ciclesonide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide nasal aerosol (CIC-HFA) 74-μg (37 μg/spray, 1 spray/each nostril)
Study: 24598007
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate monohydrate aqueous nasal spray (MFNS) 200-μg (50 μg/spray, 2 sprays/each nostril)
Study: 22374626
Drug: Cognitive restructuring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive restructuring (cognitive therapy)
Study: 22374626
Drug: Systematic desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systematic desensitization (behavioral therapy)
Study: 18323413
Drug: Testosterone and
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone and sex hormone binding globulin
Study: 11818522
Drug: Low fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fatty acid amide hydrolase (FAAH) activity in lymphocytes of IVF-embryo transfer patients who failed to achieve an ongoing pregnancy (46 +/- 17 pmol/min per mg protein)
Study: 11818522
Drug: Increased blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased blood anandamide (AEA) levels in patients who failed to achieve an ongoing pregnancy (4.0 +/- 2.2 pmol/ml)
Study: 11818522
Drug: No difference
Approvals — FDA: no, EMA: no, PMDA: no
Description: No difference in the activity of the AEA membrane transporter or amounts of cannabinoid receptors in lymphocytes between groups
Study: 26204331
Drug: Low-dose olprinone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose olprinone continuously infused for 24 hours starting just before anesthesia induction
Study: 26204331
Drug: Low-dose olprinone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose olprinone
Study: 23709289
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (3 mg/kg) before passive heat loading (PHL)
Study: 24683674
Drug: Daily Sprinkles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Sprinkles (12.5 mg of elemental iron, n = 79)
Study: 24683674
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly Sprinkles (30 mg of elemental iron, n = 73)
Study: 15342807
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human leptin treatment for up to three months
Study: 15342807
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human leptin treatment
Study: 1338742
Drug: Live enterovirus
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live enterovirus oral vaccines, administered in 2-3 doses at intervals of 7-10 days.
Study: 4014743
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or more mg of morphine
Study: 4014743
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg morphine (control)
Study: 4014743
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg morphine
Study: 31199765
Drug: Fresh coconut
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Fresh Coconut Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh coconut (100 g daily)
Study: 26865472
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal delivery system (BTDS) 5 mg
Study: 26865472
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal delivery system (BTDS) 10 mg
Study: 26865472
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal delivery system (BTDS) 20 mg
Study: 26865472
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine infusion
Study: 24828298
Drug: PUVAsol +
Normalized name: docusate sodium / sennosides, USP Oral Tablet [Purgasol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVAsol + isotretinoin (0.5 mg/kg/day)
Study: 15921865
Drug: Conjugated estrogens/medroxyprogesterone
Normalized name: Conjugated Estrogens/Medroxyprogesterone Acetate 0.625 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.625/2.5 mg daily for 24 weeks
Study: 15921865
Drug: Conjugated estrogens/medroxyprogesterone
Normalized name: Conjugated Estrogens/Medroxyprogesterone Acetate 0.625 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.45/1.5 mg daily for 24 weeks
Study: 15921865
Drug: Conjugated estrogens/medroxyprogesterone
Normalized name: Conjugated Estrogens/Medroxyprogesterone Acetate 0.625 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.3/1.5 mg daily for 24 weeks
Study: 11938636
Drug: Southern Implants
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern Implants (test group)
Study: 11938636
Drug: Southern Implants
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern Implants (control group)
Study: 10190531
Drug: Nicorandil therapy
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil therapy for 2 weeks
Study: 2253292
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 10-15 micrograms.kg-1 (Group I)
Study: 2253292
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1 (Group II)
Study: 30993861
Drug: metformin 1000-1500
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 1000-1500 mg daily
Study: 25588587
Drug: Intravenous high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high single-dose of iron isomaltoside 1000 (1,200 mg)
Study: 24114290
Drug: 0.25% topical
Normalized name: Remyda, 0.25% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% topical sodium lauryl sulfate (SLS)
Study: 24114290
Drug: 0.5% topical
Normalized name: Carac 0.5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% topical sodium lauryl sulfate (SLS)
Study: 24114290
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical sodium lauryl sulfate (SLS)
Study: 24114290
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical sodium lauryl sulfate (SLS)
Study: 19132712
Drug: Aripiprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10 mg/day for 3 days, 20 mg/day for 3 days, then 30 mg/day for 8 days)
Study: 15220020
Drug: Oxycodone/acetaminophen 5/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen 5/325 mg
Study: 11521984
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg bid for 4 weeks
Study: 2842206
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium (4 mg twice daily)
Study: 31712421
Drug: suvorexant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvorexant (20 mg)
Study: 31712421
Drug: brotizolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: brotizolam (0.25 mg)
Study: 23337558
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy (6 treatments over 4 weeks)
Study: 23337558
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (answered HIT-6 questionnaire twice before receiving treatment)
Study: 21622496
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (measured in UK units, 8 g of ethanol) in quitters
Study: 21622496
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (measured in UK units, 8 g of ethanol) in smokers
Study: 17116022
Drug: RWJ-333369 alone
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-333369 alone (5 days 250 mg q12h; 5 days 500 mg q12h)
Study: 17116022
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) alone (3 days 100 mg q12h; 3 days 200 mg q12h; 22 days 300 mg q12h)
Study: 17116022
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBZ (300 mg q12h) and RWJ-333369 (5 days 250 mg q12h; 5 days 500 mg q12h)
Study: 9255651
Drug: Intermittent furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent furosemide administration
Study: 9255651
Drug: Continuous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous furosemide infusion
Study: 28848766
Drug: Intelligent Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year
Study: 28848766
Drug: Intelligent Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year with adherence ≥70%
Study: 26481739
Drug: Intravaginal 25-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 25-μg misoprostol
Study: 23880883
Drug: Tio plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tio plus SFC (18 μg once daily + 50/250 μg twice daily)
Study: 23880883
Drug: Tio (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tio (18 μg once daily)
Study: 23880883
Drug: SM (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM (50 μg twice daily)
Study: 23880883
Drug: SFC (50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (50/250 μg twice daily)
Study: 17522609
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (50 mg/day)
Study: 17522609
Drug: Combined iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined iron and zinc supplementation (50 mg/day iron and 14 mg/day zinc)
Study: 17522609
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (14 mg/day)
Study: 12684151
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 micro g)
Study: 15070888
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 micro g)
Study: 11254789
Drug: Naltrexone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (5 mg/kg/day)
Study: 8508009
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder (daily dose, 800 mg)
Study: 30021690
Drug: Orlistat 48-mg
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 48-mg tablet
Study: 30021690
Drug: Orlistat 144-mg
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 144-mg tablet
Study: 30021690
Drug: Orlistat 24-mg
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 24-mg tablet
Study: 24728578
Drug: CP-CEF (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-CEF (carboplatin and weekly paclitaxel followed by CEF)
Study: 24728578
Drug: P-CEF (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-CEF (weekly paclitaxel followed by CEF)
Study: 22242619
Drug: Mentoring in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentoring in addition to treatment
Study: 22242619
Drug: More mentoring
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More mentoring with fewer treatment sessions
Study: 15701489
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) group (1-hour EBM journal club)
Study: 11340102
Drug: Garlic oil
Normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic oil (GO) 8.2 mg/d (allyl sulfides) for 11 weeks
Study: 11340102
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder (GP) 7.8 mg allicin/d for 11 weeks
Study: 2481163
Drug: Nifedipine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (in patients already on a beta-blocker)
Study: 27237598
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches (TNP)
Study: 23757426
Drug: Insulin-sensitizing (IS)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-sensitizing (IS) strategy
Study: 23757426
Drug: Insulin-providing (IP)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-providing (IP) strategy
Study: 23757426
Drug: Insulin-sensitizing (IS)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-sensitizing (IS) strategy in men
Study: 15331896
Drug: Switching drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching drugs after no improvement
Study: 11422094
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg acetylsalicyclic acid (ASA)
Study: 8125421
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous streptokinase)
Study: 8125421
Drug: Captopril 3
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 3 mg
Study: 8125421
Drug: Captopril (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (doses not specified)
Study: 3337794
Drug: Morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 100 micrograms kg‐1
Study: 3337794
Drug: Morphine 50
Normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 50 micrograms kg‐1
Study: 3337794
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Buprenorphine (both dosages)
Study: 3337794
Drug: Buprenorphine and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine and Morphine
Study: 26938860
Drug: Isotretinoin treatment
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin treatment for acne vulgaris for 6 months
Study: 24256373
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no isotretinoin treatment)
Study: 23848184
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g intravenous albumin for the first 3 days within the first week of ICU stay (group A)
Study: 23848184
Drug: No albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No albumin treatment (group B)
Study: 21942435
Drug: High-dose hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hydrocortisone (0.45 mg/kg IV)
Study: 21942435
Drug: Moderate-dose hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Moderate-dose hydrocortisone (0.15 mg/kg IV)
Study: 18450517
Drug: Tarenflurbil 800
Normalized name: Tarenflurbil
DrugBank: Tarenflurbil (DB05289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarenflurbil 800 mg twice per day
Study: 18450517
Drug: Tarenflurbil 800
Normalized name: Tarenflurbil
DrugBank: Tarenflurbil (DB05289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarenflurbil 800 mg twice per day for 24 months
Study: 15829988
Drug: Vardenafil (PDE-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (PDE-5 inhibitor)
Study: 12873331
Drug: Clonazepam maintenance
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam maintenance treatment (CMT)
Study: 8595686
Drug: Thiopentone 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 2.5% (50 mg)
Study: 1207275
Drug: Arginine infusion
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine infusion of 0.5 g/kg over 30 minutes